JP7819944B2 - Il-2バリアント - Google Patents

Il-2バリアント

Info

Publication number
JP7819944B2
JP7819944B2 JP2023501378A JP2023501378A JP7819944B2 JP 7819944 B2 JP7819944 B2 JP 7819944B2 JP 2023501378 A JP2023501378 A JP 2023501378A JP 2023501378 A JP2023501378 A JP 2023501378A JP 7819944 B2 JP7819944 B2 JP 7819944B2
Authority
JP
Japan
Prior art keywords
seq
cancer
protein
sequence
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2023501378A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023534793A5 (cg-RX-API-DMAC7.html
JP2023534793A (ja
Inventor
クォン、ビョン・エス.
イ、スン・ヒョン
イム、スン・ウ
チェ、ジン・キョン
ソン、ヒョン・テ
イ、ジュン・ウォン
イ、ハンナ
ファン、スンヒ
Original Assignee
ユーティレックス カンパニー リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ユーティレックス カンパニー リミテッド filed Critical ユーティレックス カンパニー リミテッド
Publication of JP2023534793A publication Critical patent/JP2023534793A/ja
Publication of JP2023534793A5 publication Critical patent/JP2023534793A5/ja
Application granted granted Critical
Publication of JP7819944B2 publication Critical patent/JP7819944B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/55—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Toxicology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
JP2023501378A 2020-07-09 2021-07-07 Il-2バリアント Active JP7819944B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063050068P 2020-07-09 2020-07-09
US63/050,068 2020-07-09
PCT/IB2021/056106 WO2022009123A1 (en) 2020-07-09 2021-07-07 Il-2 variants

Publications (3)

Publication Number Publication Date
JP2023534793A JP2023534793A (ja) 2023-08-14
JP2023534793A5 JP2023534793A5 (cg-RX-API-DMAC7.html) 2024-07-16
JP7819944B2 true JP7819944B2 (ja) 2026-02-25

Family

ID=79552299

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023501378A Active JP7819944B2 (ja) 2020-07-09 2021-07-07 Il-2バリアント

Country Status (6)

Country Link
US (1) US20230242607A1 (cg-RX-API-DMAC7.html)
EP (1) EP4185605A4 (cg-RX-API-DMAC7.html)
JP (1) JP7819944B2 (cg-RX-API-DMAC7.html)
KR (1) KR20230037612A (cg-RX-API-DMAC7.html)
CN (1) CN115768788A (cg-RX-API-DMAC7.html)
WO (1) WO2022009123A1 (cg-RX-API-DMAC7.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022053864A1 (en) * 2020-09-08 2022-03-17 Kwon Byoung S Pd-1 polypeptide variants
TWI815194B (zh) 2020-10-22 2023-09-11 美商基利科學股份有限公司 介白素2-Fc融合蛋白及使用方法
CN114853909A (zh) * 2022-05-13 2022-08-05 南京吉盛澳玛生物医药有限公司 新型IL-2与INFα和Fc融合蛋白的设计、制备及用途

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018234862A1 (en) 2017-06-19 2018-12-27 Medicenna Therapeutics Inc. Uses and methods for il-2 superagonists, agonists, and fusions thereof
WO2019239213A2 (en) 2018-06-01 2019-12-19 Medicenna Therapeutics Inc. Uses and methods for oncolytic virus targeting of il-4/il-13 and fusions thereof
WO2020020783A1 (en) 2018-07-24 2020-01-30 Biontech Rna Pharmaceuticals Gmbh Il2 agonists
WO2020069398A1 (en) 2018-09-27 2020-04-02 Akrevia Therapeutics Inc. Masked cytokine polypeptides

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012088446A1 (en) * 2010-12-22 2012-06-28 Board Of Trustees Of The Leland Stanford Junior University Superagonists and antagonists of interleukin-2
CN105440123B (zh) * 2011-02-10 2020-10-09 罗切格利卡特公司 突变体白介素-2多肽
JP6640834B2 (ja) * 2014-08-11 2020-02-05 デリニア, インコーポレイテッド 自己免疫疾患の処置のために調節性t細胞を選択的に活性化させる改変il−2変異体
WO2016100375A2 (en) * 2014-12-15 2016-06-23 Washington University Compositions and methods for targeted cytokine delivery
JP7765181B2 (ja) * 2017-12-19 2025-11-06 ゼンコア インコーポレイテッド 改変されたil-2 fc融合タンパク質
CU24554B1 (es) * 2018-05-07 2021-11-04 Ct Inmunologia Molecular Proteínas de fusión compuestas por una muteína de interleucina 2 e interferón tipo 1
CA3098930A1 (en) * 2018-09-21 2020-03-26 Innovent Biologics (Suzhou) Co., Ltd. Novel interleukin-2 and use thereof
CA3117853A1 (en) * 2018-10-29 2020-05-07 1Globe Biomedical Co., Ltd. Novel rationally designed protein compositions
AU2020285636A1 (en) * 2019-05-24 2021-11-04 Proviva Therapeutics (Hong Kong) Limited IL-2 compositions and methods of use thereof
EP4172216A4 (en) * 2020-06-24 2024-12-04 Medicenna Therapeutics, Inc. BIFUNCTIONAL SUPERKINE AND USES THEREOF
IL304365B2 (en) * 2021-03-31 2025-04-01 Hanmi Pharmaceutical Co Ltd A novel conjugate of an IL2 immunostimulatory analog and method of preparation thereof

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018234862A1 (en) 2017-06-19 2018-12-27 Medicenna Therapeutics Inc. Uses and methods for il-2 superagonists, agonists, and fusions thereof
WO2019239213A2 (en) 2018-06-01 2019-12-19 Medicenna Therapeutics Inc. Uses and methods for oncolytic virus targeting of il-4/il-13 and fusions thereof
WO2020020783A1 (en) 2018-07-24 2020-01-30 Biontech Rna Pharmaceuticals Gmbh Il2 agonists
WO2020069398A1 (en) 2018-09-27 2020-04-02 Akrevia Therapeutics Inc. Masked cytokine polypeptides

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
A next-generation tumor-targeting IL-2 preferentially promotes tumor-infiltrating CD8+ T-cell response and effective tumor control,Nat Commun.,2019年08月28日

Also Published As

Publication number Publication date
CN115768788A (zh) 2023-03-07
EP4185605A4 (en) 2024-07-17
WO2022009123A1 (en) 2022-01-13
KR20230037612A (ko) 2023-03-16
JP2023534793A (ja) 2023-08-14
EP4185605A1 (en) 2023-05-31
WO2022009123A4 (en) 2022-02-24
US20230242607A1 (en) 2023-08-03

Similar Documents

Publication Publication Date Title
Jin et al. Emerging new therapeutic antibody derivatives for cancer treatment
CN105492017B (zh) 靶向经修饰的tnf家族成员
WO2021213478A1 (zh) 抗人b7-h3的单克隆抗体及其应用
US10927183B2 (en) Anti-human VSIG4 antibodies and uses thereof
WO2023006082A1 (zh) 抗原靶向、抗cd16a和免疫效应细胞激活三功能融合蛋白及其应用
US20160297863A1 (en) Epha3 and multi-valent targeting of tumors
EP3980452A1 (en) Recombinant 4-1bb binding proteins and their use
JP2023534793A (ja) Il-2バリアント
TWI922770B (zh) 雙特異性抗體及其應用
WO2021244590A1 (zh) 抗b7-h3抗体及其制备和应用
TWI877240B (zh) 人類化抗體或其抗原結合片段、此等之製造方法及用途
JP2025098135A (ja) Pd-1ポリペプチド変異体
US12122845B2 (en) Anti-HER2/anti-4-1BB bispecific antibodies and uses thereof
CN119301159A (zh) 重组tim-4蛋白、嵌合抗原受体(car)t细胞递送系统及其制备方法和使用方法
JP7778081B2 (ja) Il-18を分泌するgpc3 car-t細胞、並びにそれを作製する方法及び使用する方法
KR102562878B1 (ko) 질환 항원이 융합된 단백질 및 이의 용도
CN110016074B (zh) Mage-a3人源化t细胞受体
CN119421898A (zh) 抗lypd3抗体
KR20250058686A (ko) Ct83 항원에 결합하는 car-t 세포 및 이의 용도
TW202409080A (zh) 用於治療卵巢癌之組合療法
HK40103619A (en) Bispecific epitope binding protein comprising anti-4-1bb antibody and pd-1 protein or fragments thereof and use thereof
CN115960248A (zh) 一种二聚体融合蛋白及其应用

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230307

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240705

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240705

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20250619

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250708

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20251006

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20260106

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20260204

R150 Certificate of patent or registration of utility model

Ref document number: 7819944

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150